论文部分内容阅读
阿西替尼(axitinib)是辉瑞公司抗肿瘤领域重要的在研药物,是一种口服的选择性血管内皮生长因子受体抑制剂。包括VEGF1受体,VECF2受体和VECF3受体。
Axitinib, an important anti-tumor drug under study in Pfizer, is an oral selective inhibitor of vascular endothelial growth factor. Including VEGF1 receptor, VECF2 receptor and VECF3 receptor.